James Daly MP has welcomed that breast cancer treatment Trodelvy has been recommended by the National Institute for Health and Care Excellence (NICE) for use on the NHS in England and will give the women who desperately need it the hope of invaluable precious extra months to live and do what matters most to them and their loved ones.
This is a momentous and hugely anticipated milestone for certain women living with incurable triple negative secondary breast cancer. Triple negative breast cancer is more common in women under 40 and affects about 15% to 20% of all women with the disease.
James Daly, MP for Bury North, commented:
“This important issue was brought to me by the brilliant Vicky Noble who has sadly passed away. Her campaigning will give the women who are facing an incredibly difficult point in their lives the chance to spend more time with their loved ones.”
“I am proud to have played a small part in this campaign by repeatedly speaking to Ministers and Gilead Sciences, who produce the treatment, but would like to pay tribute to Vicky and the campaigners who have fought so hard to make this happen. They have achieved a truly great thing that will have a massive impact on the lives of women across the UK.”
Baroness Delyth Morgan, the chief executive of Breast Cancer Now, said:
“While we are celebrating this landmark victory, we must also recognise the unacceptably difficult journey to get to this point for those affected; ten agonising months since Trodelvy was licensed by MHRA.
“Far too often, breast cancer drugs are receiving initial provisional rejections for use on the NHS and requiring multiple committee meetings, and there is urgent work to be done to ensure positive outcomes are reached far quicker for people living with breast cancer.
“Crucial lessons must be learnt to avoid scenarios like this happening again, and we’ll continue to demand more for people affected by breast cancer.”
